Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Under the auspices of the Saudi Society of Rheumatology, Saudi Society of Dermatology and Dermatologic Surgery, Saudi ...

If you are suffering from scalp conditions, such as dandruff or seborrheic dermatitis, Luke says oils might exacerbate those issues. So ask your dermatologist if oils are the right option for you ...

Skin conditions are more common than you might think, with perioral dermatitis being one of the most prevalent.

Doctors prescribe Rinvoq to treat certain inflammatory conditions, such as Crohn’s disease. A common side effect of the drug ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.